RT Journal Article
T1 Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment.
A1 Andersson, Nadine G
A1 Auerswald, Günter
A1 Barnes, Chris
A1 Carcao, Manuel
A1 Dunn, Amy L
A1 Fijnvandraat, Karin
A1 Hoffmann, Marianne
A1 Kavakli, Kaan
A1 Kenet, Gili
A1 Kobelt, Rainer
A1 Kurnik, Karin
A1 Liesner, Ri
A1 Mäkipernaa, Anne
A1 Manco-Johnson, Marilyn J
A1 Mancuso, Maria E
A1 Molinari, Angelo C
A1 Nolan, Beatrice
A1 Perez Garrido, Rosario
A1 Petrini, Pia
A1 Platokouki, Helen E
A1 Shapiro, Amy D
A1 Wu, Runhui
A1 Ljung, Rolf
K1 children
K1 factor IX
K1 factor VIII
K1 haemophilia A
K1 haemophilia B
AB The discussion of prophylactic therapy in haemophilia is largely focused on joint outcomes. The impact of prophylactic therapy on intracranial haemorrhage (ICH) is less known. This study aimed to analyse ICH in children with haemophilia, with a focus on different prophylaxis regimens and sequelae of ICH. We conducted a multicentre retrospective and prospective study that included 33 haemophilia centres from 20 countries. Inclusion criteria were children and adolescents born between 1993 and 2014, with severe haemophilia A or B without inhibitors. Participants were categorized by prophylaxis regimen: full, partial or none, based on dose and dose frequency of regular infusions. The cohort study included 1515 children: 29 cases of ICH over 8038 patient years were reported. The incidence of ICH in the prophylaxis group, 0·00033 cases of ICH/patient year, was significantly lower compared to the no prophylaxis group, 0·017 cases of ICH/patient year (RR 50·06; P 
YR 2017
FD 2017-07-12
LK http://hdl.handle.net/10668/11396
UL http://hdl.handle.net/10668/11396
LA en
DS RISalud
RD Apr 20, 2025